Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 3 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solitary Fibrous Tumor, Pleural 1Mesothelioma, Malignant 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 19Magnetic Resonance Spectroscopy 18fludarabine 15Dexamethasone 15Nivolumab 14Gemcitabine 14Bevacizumab 14Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10Docetaxel 10Cisplatin 10venetoclax 9Rituximab 9Pemetrexed 9Ipilimumab 9Prednisone 8Lenalidomide 8Fluorouracil 8blinatumomab 7Vincristine 7Radiotherapy 7Oxaliplatin 7Capecitabine 7olaparib 6lenvatinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × cediranib × 30 days × Clear all
NCT01064648 2026-05-29

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
117 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT01116648 2026-05-28

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
155 enrolled 34 charts
BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡